1Screening Status & Gaps
| Method | Se | Sp | Limit |
|---|---|---|---|
| TCT cytology | 53–81% | >90% | reproducibility |
| HR-HPV DNA | high | low | over-diagnosis |
| PAX1/JAM3 | 74.1% | 95.9% | objective |
- WHO 2021: methylation is an emerging screening direction.
- China: methylation correlates with squamous lesion severity.
2Dual-Gene Biology
PAX1 · tumor suppressor
WNT/TIMELESS
Methylation silences gene → migration & invasion.
JAM3 · adhesion
EMT / metastasis
Hypermethylation tracks FIGO stage & nodes.
- Complementary: two genes cover different profiles — dual-gene keeps high specificity while boosting sensitivity.
- Mechanism: PAX1–TCF7L2 suppresses β-catenin/MYC; JAM3 drives EMT via HIF-1α/VEGFA.
- Readout: either gene positive = positive (quantitative PCR, objective).
- PAX1 biology: paired-box transcription factor; conserved in thymus & skeletal development.
- JAM3 biology: immunoglobulin-superfamily tight-junction adhesion molecule.
- Clinical link: methylation correlates with lesion severity — a natural triage signal.
73.5%
PAX1 Se · HSIL
94%
JAM3 Sp · CIN2+
95.9%
dual Sp · CIN2+
| Key study | Setting | Methylation result |
|---|---|---|
| Chan 2025 | hrHPV+ HSIL triage | PAX1 Se 73.5% vs TCT 48.7% |
| Huang 2024 | non-16/18 CIN2+ | PAX1 OR 166.3 (high meth.) |
0.948
PAX1 AUC · CIN2
0.984
JAM3 AUC · prognosis
- Translation: dual-gene panel bridges screening & therapy decision-making.
Methylation is quantitative & reproducible — reduces cytology subjectivity & inter-observer variability.
3Evidence in Screening & Triage
0.872
AUC · CIN3+ (vs TCT 0.580)
95.9%
Sp · CIN2+
0.921
AUC · HPV16/18 triage
100%
cancer detected
| Study | Context | Key result |
|---|---|---|
| Shang · multicenter | CIN3+ triage | AUC 0.872; cancer 100% |
| Fei · HPV16/18 | 334 women | Se 89.0% / Sp 95.3% |
| Chan · HSIL | hrHPV+ triage | PAX1 Se 73.5% (AUC 0.72) |
| Huang · non-16/18 | 281 women | PAX1 AUC 0.948 CIN2 |
| Guo · prognosis | CIN1/2-3 | JAM3 AUC 0.984 / 0.966 |
Self-sampling (n=272): good concordance with clinician sampling — expands screening access.
4From Screening to Precision Care
Step 1
Screen & triage
→
Step 2
Treatment decision
→
Step 3
Prognosis & monitor
403
Chan · archival
281
Huang · non-16/18
334
Fei · HPV16/18
272
self-sampling
0.872
CIN3+ triage
0.921
HPV16/18
0.948
CIN2 (PAX1)
0.984
prognosis (JAM3)
- Guideline: PAX1 methylation in China Screening Guideline (II) biomarker system.
- Complement: fills TCT sensitivity & HPV specificity gaps; reduces over-referral.
- Next: RCT & large prospective studies for grade-A evidence.
- Objective: quantitative PCR readout independent of cytology subjectivity.
- Access: self-sampling compatibility extends screening reach.
- Cost: must fall for low-resource regions.
- QC: unified standards & multi-center validation.
One objective test spans triage, treatment guidance and follow-up — a unified molecular readout.
4Treatment Applications
Chemosensitivity
Cisplatin IC50 ↓
PAX1 reactivation: 8.01 → 3.64 μg/mL.
Radiosensitivity
OR 4.433
PAX1 hypomethylation predicts radioresistance (AUC 0.823).
Metastasis target
JAM3 / EMT
HIF-1α/VEGFA pathway — therapeutic target.
5Challenges & Outlook
Sample standardization→
Primary-care assay→
RCT / prospective
- Limitations: sample standardization, cost, quality control, low-resource adoption.
- Roadmap: unify quality standards; primary-care-adapted assays; RCT & large prospective validation.
- Positioning: complements TCT (sensitivity) & HPV (specificity) — fewer missed lesions AND fewer referrals.
- Bias risk: small studies & publication bias — multi-center confirmation needed.
- Quality: sample collection, storage & DNA extraction standardization is critical.
- Cost: equipment & transport demands currently limit broad rollout.
- Self-sampling: 272-woman cohort shows promise — expands screening access.
- Guideline: PAX1 methylation included in China Screening Guideline (II).
2025
Guideline (II) inclusion
272
self-sampling cohort
100%
cancer detection (reported)
TCT
sensitivity gap filled
HPV
specificity gap filled
QC
standardization needed
- Integration: methylation as reflex triage after hrHPV+ — fewer colposcopies, no cancer missed.
- Evidence level: mostly retrospective & single-center; RCTs awaited.
Methylation + TCT + HPV jointly optimize the screening pathway — more precise triage, less over-treatment.